TSS
PLX icon

Two Sigma Securities’s Protalix BioTherapeutics PLX Stock Holding History

Two Sigma Securities’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,811
Closed -$71.7K – 2076
2025
Q4 		$71.7K Buy
+39,811
New +$81.4K 0.01% 1022
2024
Q3 		– Sell
-52,320
Closed -$61.2K – 3463
2024
Q2 		$61.2K Sell
52,320
-32,993
-39% -$39K ﹤0.01% 2547
2024
Q1 		$107K Buy
85,313
+40,839
+92% +$61K ﹤0.01% 2467
2023
Q4 		$79.2K Buy
+44,474
New +$69.2K ﹤0.01% 2546
2023
Q3 		– Sell
-15,276
Closed -$30.6K – 3352
2023
Q2 		$30.6K Sell
15,276
-5,484
-26% -$13.1K ﹤0.01% 2457
2023
Q1 		$43.6K Buy
+20,760
New +$36.4K ﹤0.01% 2291
2018
Q1 		– Sell
-5,713
Closed -$38K – 2889
2017
Q4 		$38K Buy
5,713
+950
+20% +$6.41K ﹤0.01% 1567
2017
Q3 		$28K Buy
+4,763
New +$30.5K ﹤0.01% 797
2015
Q2 		– Sell
-1,115
Closed -$20K – 244
2015
Q1 		$20K Buy
+1,115
New +$21.8K 0.02% 177

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Two Sigma Securities's PLX Position: Q1 2026 in Review

Two Sigma Securities sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 39,811 shares — an estimated $71.7K sold.

Two Sigma Securities first reported a position in PLX in Q1 2015 and held it in 9 quarters. The position peaked at $107K in Q1 2024. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Two Sigma Securities reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 39,811 Protalix BioTherapeutics shares in Q1 2026, an estimated $71.7K.
  • Two Sigma Securities first reported a position in Protalix BioTherapeutics in Q1 2015 and held it in 9 quarters.
  • Two Sigma Securities's Protalix BioTherapeutics position peaked at $107K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.